The U.S. Food and Drug Administration (FDA) has recorded the methotrexate sodium injection (product number 001) from sponsor Quad Pharms as discontinued.
The product is an injectable formulation with a strength of EQ 25 mg base per mL. It is not designated as a reference drug, and its marketing status is listed as discontinued under application number ANDA089309.
Actualizaciones regulatorias30 ago 2026•1 min de lectura
FDA Discontinues Methotrexate Sodium Injection (ANDA089309)
The FDA has listed Quad Pharms' methotrexate sodium injection (product 001) as discontinued under ANDA089309.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración